Cellular Senescence and COVID-19 Long-Hauler Syndrome
- Conditions
- SARS-CoV2 Infection
- Registration Number
- NCT04903132
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 200
- Ability to give informed consent or LAR.
- At least 18 years old.
- Ability of subject or LAR to read and speak the English language.
- Positive PCR or antibody test within 12 months of initial study visit.
- Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
Control Cohort -
Inclusion Criteria:
- Ability to give informed consent
- At least 18 years old
- Ability of subject to read and speak the English language
Exclusion Criteria:
- Known case of COVID-19.
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
COVID-19 Control Cohort
Inclusion Criteria:
- Ability to give informed consent.
- At least 18 years old.
- Ability of subject to read and speak the English language.
- Known case of COVID-19.
Exclusion Criteria:
- Known Longhauler's syndrome/Post-COVID
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors 6 months If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States